Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025;28(6):746-754.
doi: 10.22038/ijbms.2025.82718.17878.

Evaluating ginkgetin from Ginkgo biloba as a novel agent for sleep promotion through molecular docking and in vivo studies

Affiliations

Evaluating ginkgetin from Ginkgo biloba as a novel agent for sleep promotion through molecular docking and in vivo studies

Mir Behrad Aghazadeh Ghadim et al. Iran J Basic Med Sci. 2025.

Abstract

Objectives: Sleep impacts the well-being and quality of life of millions. Given conventional pharmacotherapy's limitations and side effects, the quest for adequate and proper sleep promotion is imperative. This study aims to identify a suitable and effective compound for sleep by examining qualified herbal compounds in the PubChem database using in silico methods. Ultimately, the extracted compound (ginkgetin, a bioactive flavonoid from Ginkgo biloba) through molecular docking by considering the GABAA receptors will be evaluated through the in vivo method in an animal model to serve as proof for the findings from the molecular docking process.

Materials and methods: Utilizing a comprehensive approach, this research employed molecular docking to screen 2299 phytochemicals for their affinity towards the GABAA receptor, focusing on the GABA, benzodiazepine, and steroid-binding sites. Ginkgetin emerged as a top candidate due to its high binding affinity. Subsequent in vivo electrophysiological assessments in rats treated with G. biloba extract containing ginkgetin evaluated alterations in sleep architecture, REM, and NREM sleep phases.

Results: Molecular docking identified ginkgetin as possessing the highest binding affinity among the screened phytochemicals. In vivo studies corroborated these findings, demonstrating that rats treated with Ginkgo biloba extract significantly enhanced REM and NREM sleep compared to controls.

Conclusion: Ginkgetin, derived from G. biloba, shows promising potential as a novel therapeutic agent for sleep disorders, supported by its strong affinity to key receptor sites and its efficacy in modulating sleep architecture in vivo. These findings contribute to the expanding evidence base for the therapeutic use of G. biloba in sleep promotion and underscore the need for further research to elucidate the mechanisms and clinical applicability of ginkgetin in sleep disorder treatment.

Keywords: GABAA receptor; Ginkgetin; Ginkgo biloba; Molecular docking; Sleep.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests to disclose.

Figures

Figure 1
Figure 1
Analysis method: High-performance thin layer chromatography
Figure 2
Figure 2
Molecular interaction profile of ginkgetin with GABAA receptor binding sites
Figure 3
Figure 3
Correlation of predicted binding energies by AutoDock4 and Vina
Figure 4
Figure 4
Comparative effects of Ginkgo biloba and valerian extracts on sleep architecture
Figure 5
Figure 5
Hypnogram of Ginkgo biloba extract administration

Similar articles

References

    1. Wu C, Sun D. GABA receptors in brain development, function, and injury. Metab Brain Dis. 2015;30:367–379. - PMC - PubMed
    1. Ghit A, Assal D, Al-Shami AS, Hussein DEE. GABA(A) receptors: Structure, function, pharmacology, and related disorders. J Genet Eng Biotechnol. 2021;19:123–138. - PMC - PubMed
    1. Simeone TA, Donevan SD, Rho JM. Molecular biology and ontogeny of gamma-aminobutyric acid (GABA) receptors in the mammalian central nervous system. J Child Neurol. 2003;18:39–48. - PubMed
    1. Ferranti AS, Luessen DJ, Niswender CM. Novel pharmacological targets for GABAergic dysfunction in ADHD. Neuropharmacology . 2024:109897–109915. - PMC - PubMed
    1. Koche D, Shirsat R, Kawale M. An overerview of major classes of phytochemicals: their types and role in disease prevention. Hislopia J. 2016;9:1–11.

LinkOut - more resources